Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.
Vertex Pharmaceuticals (NASDAQ: VRTX) has churned out nice profits quarter after quarter for years. The big biopharmaceutical company's cystic fibrosis (CF) franchise made it easy.
However, Vertex announced its second-quarter results following the market close on Thursday. Lo and behold, the company posted a net loss of $3.6 billion, based on generally accepted accounting principles (GAAP). Its non-GAAP loss was $3.3 billion.
Should investors worry about this big loss? Not even for a second.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
€430.00
-0.230%
With 57 Buy predictions and 2 Sell predictions Vertex Pharmaceuticals Inc. is one of the favorites of our community.
As a result the target price of 440 € shows a slightly positive potential of 2.33% compared to the current price of 430.0 € for Vertex Pharmaceuticals Inc..
